Association of Laparoscopic Gastric Bypass Surgery With Telomere Length in Patients With Obesity
Severe obesity is the leading public health crisis in the industrialized world and affects men and women of all races/ethnicities and socioeconomic status.
1 Along with obesity, aging-related dementia risk factors include insulin resistance, lipid abnormality, and inflammation. 2, 3 Other age-related changes include telomere shortening, which has implications such as genomic instability and cancer and has been shown to be associated with high body mass index (calculated as weight in kilograms divided by height in meters squared). 4 Telomeres are repeating strands of DNA that flank mammalian chromosomes and thus protect coding DNA from progressive degradation after each replication. In the peripheral blood, telomeres progressively shorten with the aging process and have a negative correlation with oxidative stress and a severe inflammatory state. 3, 4 Data are currently mixed on the association between surgical weight loss and telomere length. 5, 6 Our primary goal in this study was to examine whether telomeres lengthen in obese patients before and after laparoscopic gastric bypass surgery. sis, and Spearman and Pearson correlations were used to analyze data. A 2-sided P < .05 was considered to be statistically significant. Patients provided written informed consent, and all data were deidentified. The study was approved by the Stanford University Institutional Review Board.
Methods
Results | The demographic distribution in the 51 patients in this study (mean age, 48.6 years; age range, 19.0-68.0 years; 39 [76%] female) was representative of the overall population undergoing bariatric surgery. By 12 postoperative months, the mean body mass index reduction was 12.2, and the amount of excess weight loss was 70.4% (P = .01). In addition, the following cardiometabolic risk factor means changed from before to 12 months after the operation: CRP level, 6.7 to 3.6 mg/L (P = .12) (to convert to nanomoles per liter, multiply by 9.524; LDL-C level, 96.8 to 102 mg/dL (P = .58) (to convert to millimoles per liter, multiply by 0.0259); and HDL-C level, 45.3 to 56.3 mg/dL (P = .004) (to convert to millimoles per liter, multiply by 0.0259). For all patients, mean telomere length was not statistically different from before (0.987) to 12 months after the operation (0.982) (P = .76). However, when patients were categorized by inflammatory and lipid markers, significant differences in telomere length emerged over time. Patients with a preoperative LDL-C level greater than 140 mg/dL had significant telomere lengthening compared with patients with low LDL-C levels (−0.0271 [normal LDL-C] vs +0.0227 [abnormal LDL-C], P = .04). Preoperatively, the mean CRP level for all patients was 7 mg/L. Patients with a preoperative CRP level of greater than 7 mg/L had significant telomere lengthening compared with patients with low CRP levels (−0.02294 [low CRP] vs +0.04125 [high CRP], P = .005) (Figure) . Furthermore, in the group of patients with high CRP levels, a significant positive correlation was found between weight loss and telomere length (r = 0.879, P = .0498) as well as between change in HDL-C level and increase in telomere length (r = 0.842. P = .02).
Conclusions | In this study, surgical weight loss was associated with lengthening of telomeres in patients who had an adverse cardiometabolic state before surgery. Although this study is limited by the small study population and a single site intervention, this finding suggests that the greatest potential benefit for slowing the aging process as expressed by telomere lengthening is in patients with the most comorbidity before surgery. Further study is needed with greater numbers and diversity of procedures. Finally, the study demonstrated an association among obesity, inflammation, and the aging process. Quantitative polymerase chain reaction was used to create a relative telomere to single copy gene ratio, which is proportional to mean telomere length. CRP indicates high-sensitivity C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. COMMENT & RESPONSE
Errors in Analysis in Study of New Persistent Opioid Use After Surgery
To the Editor On behalf of our coauthors, we write to explain an error that we have discovered in our analysis for the Original Investigation titled, "New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults," published online April 12, 2017, in JAMA Surgery. 1 In this article, we reported our study of US nationwide insurance claims data and adults without opioid use prior to undergoing a surgical procedure. We compared the incidence of new persistent opioid use (more than 90 days after surgery) among those undergoing minor vs major surgical procedures and compared the incidences with new opioid use in a nonoperative control group. For the primary study outcome, we found similar rates of persistent opioid use among those undergoing minor and major surgical procedures, ranging from 5.9% to 6.5%, and the incidence in the nonoperative control group was 0.4%. We identified risk factors associated with new persistent opioid use, including tobacco use, alcohol and substance use disorders, mood disorders, anxiety, and preoperative pain disorders (ie, back pain, neck pain, arthritis, and centralized pain). We concluded, "New persistent opioid use after surgery is common and is not significantly different between minor and major surgical procedures but rather associated with behavioral and pain disorders."
1 While working on another data set using similar data derived from OptumInsight (the company affiliated with the administrative health claims data set used in our study), one of us (S.E.M.) realized that the indicators for presurgical diagnoses of mental and physical health conditions were actually indicators for these conditions at any point 1 year prior to surgery (the defined preoperative period in the article) to 1-year postsurgery. The analysis has been rerun using only the presurgical diagnoses for these mental and physical health diagnoses, excluding those who received their diagnoses after surgery, as was planned in our original analysis. As a result of this reanalysis, we identified relatively small numerical errors in the overall frequencies, coefficients, and P values that were reported in our original article. However, these errors do not change the primary outcome or the overall conclusions of the study. The effect sizes for the individual patient characteristics independently associated with new persistent opioid use were relatively small in both the original and revised analyses. A second data analyst has reviewed both the original and revised analyses, and we can confirm that there are no other errors to report.
Herein, we note the 4 presurgical characteristics that changed in statistical significance from the published univariate results in Table 1 . 1 In the originally published table, significant differences for the "Disruptive" and "Other" rows were reported between persistent users and nonpersistent users in the minor surgery cohort. In the corrected analysis, these 2 predictors were no longer statistically significant. In addition, in the original table, significant differences for the "Suicide or self-harm" and "Other pain conditions" rows were reported between persistent and nonpersistent users in the major surgery cohort. In the corrected analysis, these predictors were no longer statistically significant. We also note the 1 presurgical characteristic that has changed in statistical significance from the published multivariate model in Table 2 . 1 In the originally published table, the "Neck" row was reported to be significantly associated with new persistent opioid use (adjusted odds ratio, 1.22; 95% CI, 1.07-1.39; P = .002). In the corrected analysis, presurgical neck pain was not significantly associated with persistent opioid use (adjusted odds ratio, 1.11; 95% CI, 0.95-1.29; P = .19). Finally, there was 1 typo that was corrected in Table 1 . 1 In the "College degree or more row" of the major surgery cohort section, the cell in the "No Persistent Opioid Use" column should read 978. The corrections affect the Abstract, Results section, and Tables 1 and 2 . 1 We have requested that the original article be corrected online. 2 We regret the errors and any confusion this has caused and appreciate the opportunity to offer these corrections.
